Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $292000.0.

  • Taysha Gene Therapies' Other Non Operating Income rose 46049.38% to $292000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $286000.0, marking a year-over-year increase of 10043.55%. This contributed to the annual value of -$110000.0 for FY2024, which is 10031.68% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Other Non Operating Income of $292000.0 as of Q3 2025, which was up 46049.38% from $273000.0 recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Other Non Operating Income peaked at $100.5 million during Q3 2023, and registered a low of -$65.7 million during Q4 2023.
  • In the last 4 years, Taysha Gene Therapies' Other Non Operating Income had a median value of -$4500.0 in 2022 and averaged $2.5 million.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Other Non Operating Income showed a top increase of 1004570000.0% in 2023 and a maximum decrease of 109553333.33% in 2023.
  • Taysha Gene Therapies' Other Non Operating Income (Quarter) stood at -$6000.0 in 2022, then crashed by 1095533.33% to -$65.7 million in 2023, then soared by 99.73% to -$177000.0 in 2024, then surged by 264.97% to $292000.0 in 2025.
  • Its last three reported values are $292000.0 in Q3 2025, $273000.0 for Q2 2025, and -$102000.0 during Q1 2025.